| 24 Mar, 05:14 pm | — | … | Natco Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on March 24, 2026 | nse |
| 20 Mar, 09:34 am | — | … | Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 20 Mar, 09:31 am | — | … | Natco Pharma Limited has informed the Exchange regarding a press release dated March 20, 2026, titled "NATCO Pharma Launches Semaglutide Generic Injection Multi Dose Vials in India at the Most Affordable Price Starting from MRP INR 1,290". | nse |
| 18 Mar, 04:13 pm | — | … | Natco Pharma Ltd - 524816 - Board Meeting Intimation for Approving The Scheme Of Arrangement (Demerger) | bse |
| 13 Mar, 04:28 pm | — | … | Natco Pharma Ltd - 524816 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 | bse |
| 13 Mar, 04:26 pm | — | … | Natco Pharma Ltd - 524816 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 | bse |
| 03 Mar, 10:32 am | — | … | Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 03 Mar, 10:29 am | — | … | Natco Pharma Limited has informed the Exchange regarding a press release dated March 03, 2026, titled "NATCO announces launch of Pomalidomide Capsules (generic of Pomalyst®) in the U.S. market". | nse |
| 25 Feb, 12:03 pm | — | … | Natco Pharma Ltd - 524816 - Clarification On Volume Movement Of Shares | bse |
| 25 Feb, 10:06 am | — | … | Natco Pharma Ltd - 524816 - Rumour verification - Regulation 30(11) | bse |
| 25 Feb, 10:02 am | — | … | The Exchange has sought clarification from Natco Pharma Limited with respect to recent news item captioned Eris Lifesciences inks deal with Natco Pharma for weight-loss drug semaglutide.. The response from the Company is attached. | nse |
| 24 Feb, 04:54 pm | — | … | The Exchange has sought clarification from Natco Pharma Limited with respect to recent news item captioned Eris Lifesciences inks deal with Natco Pharma for weight-loss drug semaglutide.. The response from the Company is awaited. | nse |
| 18 Feb, 03:40 pm | — | … | Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | bse |
| 18 Feb, 03:35 pm | — | … | Natco Pharma Limited has informed the Exchange about Transcript | nse |
| 14 Feb, 09:31 am | — | … | Natco Pharma Limited has informed the Exchange regarding a press release dated February 14, 2026, titled "NATCO receives approval from Central Drugs Standard Control Organisation (CDSCO) for Semaglutide in India". | nse |
| 14 Feb, 09:26 am | — | … | Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 13 Feb, 09:18 am | — | … | Natco Pharma Limited has informed the Exchange regarding a press release dated February 13, 2026, titled "Press Release regarding the receipt of Establishment Inspection Report (EIR) for the API Unit located in Chennai from U.S. Food and Drug Administration (FDA)". | nse |
| 13 Feb, 09:16 am | — | … | Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 12 Feb, 06:07 pm | — | … | Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | bse |
| 12 Feb, 06:03 pm | — | … | Natco Pharma Limited has informed the Exchange about Link of Recording for the Concall held on 12th February, 2026 | nse |
| 12 Feb, 04:00 pm | — | … | Natco Pharma Ltd - 524816 - Corporate Action-Board approves Dividend | bse |
| 12 Feb, 03:58 pm | — | … | Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Meeting Updates | bse |
| 12 Feb, 03:54 pm | — | … | Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Change in Management | bse |
| 12 Feb, 03:49 pm | — | … | Natco Pharma Limited has informed the Exchange that Record date for the purpose of Dividend is 18-Feb-2026. | nse |
| 12 Feb, 03:48 pm | — | … | Natco Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on February 12, 2026. | nse |
| 12 Feb, 03:45 pm | — | … | Natco Pharma Limited has informed the Exchange regarding Appointment of Mr K Srinivasa Rao as Executive Vice President - Pharma Division of the company w.e.f. February 12, 2026. | nse |
| 12 Feb, 03:45 pm | — | … | Natco Pharma Limited has informed the Exchange regarding Cessation of Mr S V V N Appa Rao as Chief Financial Officer of the company w.e.f. February 12, 2026. | nse |
| 12 Feb, 03:45 pm | — | … | Natco Pharma Limited has informed the Exchange regarding Appointment of Mr Amit Parekh as Chief Financial Officer of the company w.e.f. February 13, 2026. | nse |
| 12 Feb, 03:04 pm | — | … | Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation | bse |
| 12 Feb, 03:02 pm | — | … | Natco Pharma Limited has informed the Exchange about Investor Presentation | nse |
| 12 Feb, 02:49 pm | — | … | Natco Pharma Ltd - 524816 - Un Audited Financial Results For The Quarter Ending 31St December, 2025 | bse |
| 12 Feb, 02:40 pm | — | … | Natco Pharma Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025 and declaration of 3rd Interim Dividend of Rs.1.50 per share for the fy 2025-26 | nse |
| 12 Feb, 02:35 pm | — | … | Natco Pharma Ltd - 524816 - Board Meeting Outcome for Out Come Of Board Meeting | bse |
| 12 Feb, 02:32 pm | — | … | Natco Pharma Limited has informed the Exchange that Board of Directors at its meeting held on February 12, 2026, declared Interim Dividend of 1.50 per equity share. | nse |
| 03 Feb, 02:54 pm | — | … | Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 03 Feb, 02:50 pm | — | … | Natco Pharma Limited has informed the Exchange regarding a press release dated February 03, 2026, titled "NATCO receives Tentative Approval for Erdafitinib Tablets (generic of Balversa®) from the United States Food and Drug Administration (U.S. FDA)". | nse |
| 03 Feb, 01:19 pm | — | … | Natco Pharma Limited has informed the Exchange regarding a press release dated February 03, 2026, titled "NATCO receives Tentative Approval for Erdafitinib Tablets (generic of Balversa®)". | nse |
| 03 Feb, 01:17 pm | — | … | Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 02 Feb, 04:11 pm | — | … | Natco Pharma Limited has informed the Exchange about Schedule of Q3FY26 Un-audited Financial Results Earnings Call | nse |
| 30 Jan, 12:43 pm | — | … | Natco Pharma Limited has informed the Exchange regarding a press release dated January 30, 2026, titled "Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015". | nse |
| 28 Jan, 03:47 pm | — | … | Natco Pharma Ltd - 524816 - Board Meeting Intimation for Considering The Unaudited Financial Results For The Quarter And Period Ended 31St December, 2025 And Declaration Of 3Rd Interim Dividend, If Any For FY 2025-26 | bse |
| 07 Jan, 11:50 am | — | … | The Exchange has sought clarification from Natco Pharma Limited with respect to recent news item captioned HC seeks Novo Nordisk's reply on Natco plea to revoke patent. The response from the Company is attached. | nse |
| 07 Jan, 10:55 am | — | … | The Exchange has sought clarification from Natco Pharma Limited with respect to recent news item captioned HC seeks Novo Nordisk's reply on Natco plea to revoke patent. The response from the Company is awaited. | nse |
| 05 Jan, 05:11 pm | — | … | Natco Pharma Limited has informed the Exchange regarding 'Sustainability Report for the year 2024-25'. | nse |
| 02 Dec, 12:34 pm | — | … | Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Change in Management | bse |
| 02 Dec, 12:34 pm | — | … | Natco Pharma Limited has informed the Exchange regarding Appointment of Mr AMIT PAREKH as Other of the company w.e.f. December 02, 2025. | nse |
| 29 Nov, 09:51 am | — | … | Natco Pharma Limited has informed the Exchange about Credit Rating | nse |
| 29 Nov, 09:49 am | — | … | Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Credit Rating | bse |
| 21 Nov, 04:15 pm | — | … | Natco Pharma Limited has informed the Exchange regarding a press release dated November 21, 2025, titled "Conclusion of FDA Inspection at our Manali, Chennai API Unit". | nse |
| 21 Nov, 04:12 pm | — | … | Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |